Who are docetaxel plus oxaliplatin and capecitabine's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): epirubicin , pirarubicin , hydroxycamptothecin and fluorouracil, carboplatin/cisplatin-etoposide, Tislelizumab plus Carboplatin and Paclitaxel.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/docetaxel-plus-oxaliplatin-and-capecitabine.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-17 · How we verify

docetaxel plus oxaliplatin and capecitabine — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

docetaxel plus oxaliplatin and capecitabine (docetaxel plus oxaliplatin and capecitabine) competitive landscape: 3 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: chemotherapeutic agents. Area: Oncology.

phase 3 chemotherapeutic agents Oncology Small molecule Live · refreshed every 30 min

Target snapshot

docetaxel plus oxaliplatin and capecitabine (docetaxel plus oxaliplatin and capecitabine) — LiNing. Docetaxel works by inhibiting microtubule dynamics, while oxaliplatin induces DNA damage and interstrand crosslinks, and capecitabine is a thymidylate synthase inhibitor.

Comparator set (3 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
docetaxel plus oxaliplatin and capecitabine TARGET	docetaxel plus oxaliplatin and capecitabine	LiNing	phase 3	chemotherapeutic agents
epirubicin , pirarubicin , hydroxycamptothecin and fluorouracil	epirubicin , pirarubicin , hydroxycamptothecin and fluorouracil	Sun Yat-sen University	phase 3	anthracycline and antimetabolite chemotherapeutic agents
carboplatin/cisplatin-etoposide	carboplatin/cisplatin-etoposide	Shanghai Henlius Biotech	phase 3	platinum-based chemotherapeutic agents	DNA
Tislelizumab plus Carboplatin and Paclitaxel	Tislelizumab plus Carboplatin and Paclitaxel	RemeGen Co., Ltd.	phase 3	PD-1 inhibitor and chemotherapeutic agents	PD-1

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (chemotherapeutic agents class)

LiNing · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). docetaxel plus oxaliplatin and capecitabine — Competitive Intelligence Brief. https://druglandscape.com/ci/docetaxel-plus-oxaliplatin-and-capecitabine. Accessed 2026-05-17.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab